The Electrocardiogram.

In jeopardy more than a century after its introduction by Willem Einthoven?

Time for a revival.

by

Hein J. Wellens MD
The ECG

- Everywhere available
- Easy and rapid to make
- Non-invasive
- Reproducible
- Inexpensive
- Patient-friendly
The time is at hand, if not already come, when an examination of the heart is incomplete if this new method is neglected.

Thomas Lewis 1912

I do not imagine that electrocardiography is likely to find any very extensive use in the hospital. It can at most be of rare and occasional use to afford a record of some rare anomaly of cardiac action.

Augustus D. Waller 1911

Not so evident at the beginning…

Einthoven, Nobel Lecture, December 11, 1925

the English investigator Thomas Lewis, ... has played a great part in the development of electrocardiography..., and I doubt whether without his valuable contributions I should have the privilege of standing before you today

Lewis developed clinical electrocardiology
• Every day approximately **3.000.000 ECGs are made worldwide!**

• The **ECG is not only the tool most used but also the most valuable one giving instantaneous information about the heart.**

By re-analyzing the ECG in the light of findings from invasive and non-invasive studies (coronary angiography, programmed electrical stimulation of the heart, intracardiac mapping, echo, MRI, nuclear, genetic information) and by using computer-assisted measurements, correlations and predictions the diagnostic value of the ECG continues to grow.
The ECG

**Instantaneous information on diagnosis, management and effect of treatment:**

- Cardiac ischemia
- Rhythm- and conduction disturbances
- Structural changes in the cardiac chambers
- ECG changes caused by medication
- Evaluation and programming implantable devices
- Electrolyte and metabolic disorders
- Monogenic arrhythmology

**Risk estimation**

---

**The value of the ECG in cardiac ischemia**

- **Presence and staging of the ischemic process**
- **Localization of the site and size of the area at risk by determing the location of the culprit lesion in the coronary artery**
- **Diagnosing reperfusion**
- **Localizing extent of muscle loss**
- **Predictor of future cardiac events**
The ECG in Rhythm and Conduction disturbances

- Localizing the site of block
- Determining the type of tachycardia
- Localizing the site of origin or circuit of the tachycardia
- Determining the mechanism of a tachycardia
- Selecting optimal management

Risk of sudden cardiac death

<table>
<thead>
<tr>
<th></th>
<th>% SCD</th>
<th>Predictability</th>
</tr>
</thead>
<tbody>
<tr>
<td>No hx of cardiac disease</td>
<td>45</td>
<td>Poor</td>
</tr>
<tr>
<td>Hx cardiac event: LVEF &gt; 40%</td>
<td>40</td>
<td>Limited</td>
</tr>
<tr>
<td>Hx cardiac event: LVEF &lt; 40%</td>
<td>13</td>
<td>Possible</td>
</tr>
<tr>
<td>Monogenic arrhythm disease</td>
<td>2</td>
<td>Limited</td>
</tr>
</tbody>
</table>
The ECG for risk estimation sudden cardiac death

- Heart rate variability turbulence
- Deceleration capacity after a VPB
- QRS width notching signal averaging
- Left ventricular hypertrophy
- QT interval length dispersion dynamic behavior
- T wave alternans
- Angle QRS complex – T wave
- Exercise ECG
- Monogenic electrocardiography

ECG derived risk stratifiers reported to have prognostic value for overall cardiac and sudden death mortality in different clinical settings (1)

<table>
<thead>
<tr>
<th>Sinus Rhythm</th>
<th>GP</th>
<th>pLVEF</th>
<th>rLVEF</th>
<th>12 lead ECG</th>
<th>Holter</th>
</tr>
</thead>
<tbody>
<tr>
<td>- Resting rate and profile during exercise</td>
<td>+</td>
<td>+</td>
<td>?</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>- Rate variability</td>
<td>+/-</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>- Heart rate turbulence</td>
<td>?</td>
<td>++</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>- Deceleration capacity</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>-</td>
<td>+</td>
</tr>
<tr>
<td>Atrial dilatation</td>
<td>?</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Atrial fibrillation</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>AV conduction</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>- Site of AV block</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>- Presence of accessory pathways</td>
<td>+</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>+</td>
</tr>
</tbody>
</table>

GP = general population; pLVEF=cardiac disease, preserved LVEF; rLVEF= cardiac disease, reduced LVEF
### ECG derived risk stratifiers reported to have prognostic value for overall cardiac and sudden death mortality in different clinical settings (2)

<table>
<thead>
<tr>
<th>QRS</th>
<th>GP</th>
<th>pLVEF</th>
<th>rLVEF</th>
<th>12 lead ECG</th>
<th>Holter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Width &gt; 100 ms</td>
<td>?</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Left bundle branch block</td>
<td>+</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Notching, fractionation</td>
<td>?</td>
<td>+</td>
<td>++</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Number &amp; location of Q waves</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Reduced voltage (limb leads)</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>SAECG</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Left ventricular hypertrophy</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Mean QRS-T angle</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

GP = general population; pLVEF = cardiac disease, preserved LVEF; rLVEF = cardiac disease, reduced LVEF; SAECG = signal averaged ECG

### ECG derived risk stratifiers reported to have prognostic value for overall cardiac and sudden death mortality in different clinical settings (3)

<table>
<thead>
<tr>
<th>QT interval</th>
<th>GP</th>
<th>pLVEF</th>
<th>rLVEF</th>
<th>12 lead ECG</th>
<th>Holter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Duration</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>+</td>
</tr>
<tr>
<td>Dispersion</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>Dynamic</td>
<td>?</td>
<td>+</td>
<td>+</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ST-segment</th>
<th>GP</th>
<th>pLVEF</th>
<th>rLVEF</th>
<th>12 lead ECG</th>
<th>Holter</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elevation/depression</td>
<td>+/-</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>-</td>
</tr>
<tr>
<td>J-point elevation (inferior leads)</td>
<td>+</td>
<td>?</td>
<td>?</td>
<td>+</td>
<td>-</td>
</tr>
</tbody>
</table>

GP = general population; pLVEF = cardiac disease, preserved LVEF; rLVEF = cardiac disease, reduced LVEF;
ECG derived risk stratifiers reported to have prognostic value for overall cardiac and sudden death mortality in different clinical settings (4)

Presence of these different ECG risk-stratifiers gives information about:

- A possible tachycardia substrate
- Tachycardia triggers
- The most likely tachycardia mechanism
- Autonomic status
- Genetic background
- Effect of management
Challenge

What will be the best combination of these ECG derived risk stratifiers in different clinical settings using the 12 lead ECG and Holter?

Progress in recent years using the ECG

Examples:
- The ECG in LBBB
- The ECG to localize the coronary occlusion site in acute MI
Important questions when analysing the LBBB ECG

1. QRS width
2. QRS axis in the frontal plane?
3. QRS voltage extremity leads vs precordial leads?
4. Notching in second half of QRS?
5. Duration of P-R interval?
6. RV enlargement/dysfunction?
ECG findings indicating poor prognosis in LBBB

1. QRS width: the wider the worse!
2. QRS axis in frontal plane: superior axis is bad news.
3. Low QRS voltage extremity leads: bad news.
4. Notching in second half QRS: scar
5. Prolonged PR interval

Wide QRS-Proportional Mortality Increase

Vesnarinone Study\(^1\)
(VEST study analysis)

- NYHA Class II-IV patients
- 3,654 ECGs digitally scanned
- Age, creatinine, LVEF, heart rate, and QRS duration found to be independent predictors of mortality
- Relative risk of widest QRS group 5x greater than narrowest

\(^1\) Gottipaty V, Krelis S, et al. ACC 1999 [Abstr]:847-4
ECG findings indicating poor prognosis in LBBB

1. QRS width: the wider the worse!
2. QRS axis in frontal plane: superior axis is bad news.
3. Low QRS voltage extremity leads: bad news.
4. Notching in second half QRS: scar
5. Prolonged PR interval
Frontal QRS axis in LBBB

Superior axis indicates both left and right ventricular enlargement!

ECG findings indicating poor prognosis in LBBB

1. QRS width: the wider the worse!
2. QRS axis in frontal plane: superior axis is bad news.
3. Low QRS voltage extremity leads: bad news.
4. Notching in second half QRS: scar
5. Prolonged PR interval
ECG findings indicating poor prognosis in LBBB

1. QRS width: the wider the worse!
2. QRS axis in frontal plane: superior axis is bad news.
3. Low QRS voltage extremity leads: bad news.
4. Notching in second half QRS: scar
5. Prolonged PR interval

Atrial fibrillation and LBBB
QRS width: 200 ms
QRS axis: superior
Low volt. extr. leads/high volt. prec. leads
Conclusion: marked enlargement LV and RV

Atrial fibrillation and LBBB
QRS width: 200 ms
QRS axis: -60°
Higher voltage extremity leads
Conclusion: decrease in RV enlargement
ECG findings indicating poor prognosis in LBBB

1. QRS width: the wider the worse!
2. QRS axis in frontal plane: superior axis is bad news.
3. Low QRS voltage extremity leads: bad news.
4. Notching in second half QRS: scar
5. Prolonged PR interval
ECG findings indicating poor prognosis in LBBB

1. QRS width: the wider the worse!
2. QRS axis in frontal plane: superior axis is bad news.
3. Low QRS voltage extremity leads: bad news.
4. Notching in second half QRS: scar
5. Prolonged PR interval

LV activation in LBBB 50-60 ms after start RV activation
diastolic MI
reduced LV filling
How to diagnose right ventricular enlargement in the patient with LBBB?

Criteria for RV dilatation in LBBB:
1. Terminal positivity in lead aVR (late R in aVR)
2. Low voltage (< 0.6 mV) in all extremity leads
3. A R/S ratio < 1 in lead V6
**Criteria for RV dilatation in LBBB**

1. Terminal positivity in lead aVR (late R in aVR)
2. Low voltage (< 0.6 mV) in all extremity leads
3. A R/S ratio < 1 in lead V5

> 2 Criteria positive:
  + PV 89%
  - PV 88%

Van Bommel RJ et al; Am J Cardiol 2011; 107:736-740

In acute cardiac ischemia the exact site of occlusion in the coronary artery and thereby the size of the area at risk is indicated by the direction of the deviation of the ST segment, because the ST segment deviation vector points to the dominant ischemic area. This knowledge is important to recognize a proximal coronary occlusion!
Increasing super-specialization in cardiology threatens the implementation of new ECG knowledge in daily cardiology practice.

Both old and recent knowledge of the ECG should be in the core curriculum of every cardiologist, not only during the training phase but also during postgraduate education!

How to use the ECG to localize the exact site of the coronary artery occlusion in the patient with acute chest pain?
The ST deviation vector points to the dominant area of cardiac ischemia revealing the site and size of the area at risk and the location of the occlusion in the culprit coronary artery.